The Wistar Institute
- Country
- 🇺🇸United States
- Ownership
- Private
- Established
- 1972-01-01
- Employees
- 501
- Market Cap
- -
- Website
- http://www.wistar.org
Clinical Trials
5
Trial Phases
3 Phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (5 trials with phase data)• Click on a phase to view related trials
Reducing Proviral HIV DNA With Interferon-a
- Conditions
- HIVHIV/AIDS
- Interventions
- Drug: Peg-IFN-α2b
- First Posted Date
- 2014-08-28
- Last Posted Date
- 2018-04-05
- Lead Sponsor
- The Wistar Institute
- Target Recruit Count
- 54
- Registration Number
- NCT02227277
- Locations
- 🇺🇸
Hospital of the University of Pennsylvania, Philadelphia, Pennsylvania, United States
🇺🇸Penn-Presbyterian Hospital, Philadelphia, Pennsylvania, United States
🇺🇸Jonathan Lax Center at Philadelphia FIGHT, Philadelphia, Pennsylvania, United States
Pilot Peg-Interferon-a2b in Decreasing Viral DNA in HIV
- Conditions
- HIV-1 Infection
- Interventions
- Drug: Pegylated Interferon alpha 2b
- First Posted Date
- 2013-09-04
- Last Posted Date
- 2023-07-06
- Lead Sponsor
- The Wistar Institute
- Target Recruit Count
- 20
- Registration Number
- NCT01935089
- Locations
- 🇺🇸
AIDS Clinical Trials Unit (ACTU), and Department of Medicine, University of Pennsylvania Perelman School of Medicine, Philadelphia, Pennsylvania, United States
🇺🇸Presbyterian Hospital, Department of Medicine, University of Pennsylvania Perelman School of Medicine, Philadelphia, Pennsylvania, United States
🇺🇸Jonathan Lax Clinic, Philadelphia FIGHT, Philadelphia, Pennsylvania, United States
Antiviral Activity of Peg-IFN-Alpha-2A in Chronic HIV-1 Infection
- Conditions
- HIV Infections
- Interventions
- Drug: Pegylated Interferon-alpha 2a, 180 mcg/week scDrug: Pegylated Interferon-alpha 2a, 90 mcg/week sc
- First Posted Date
- 2008-01-16
- Last Posted Date
- 2015-02-10
- Lead Sponsor
- The Wistar Institute
- Target Recruit Count
- 23
- Registration Number
- NCT00594880
- Locations
- 🇺🇸
Drexel University College of Medicine, Philadelphia, Pennsylvania, United States
🇺🇸Hospital of the University of Pennsylvania, Philadelphia, Pennsylvania, United States
🇺🇸Penn-Presbyterian Medical Center, Philadelphia, Pennsylvania, United States
Anti-HIV Treatment Interruptions in HIV Infected Adults in South Africa
- Conditions
- HIV Infections
- Interventions
- Behavioral: Structured treatment interruptionBiological: Rabies de novo antigen
- First Posted Date
- 2005-01-05
- Last Posted Date
- 2014-08-27
- Lead Sponsor
- The Wistar Institute
- Target Recruit Count
- 30
- Registration Number
- NCT00100646
- Locations
- 🇿🇦
University of the Witwatersrand, Johannesburg, South Africa
Immune and Viral Outcomes of HIV-1 Therapy Interruption
- Conditions
- HIV Infections
- First Posted Date
- 2003-01-24
- Last Posted Date
- 2016-02-09
- Lead Sponsor
- The Wistar Institute
- Target Recruit Count
- 20
- Registration Number
- NCT00051818
- Locations
- 🇺🇸
The Wistar Institute, Philadelphia, Pennsylvania, United States
News
Wistar Institute Launches $17 Million Personalized HIV Cure Initiative with Six-Component Therapy Approach
The Wistar Institute received a five-year, $17 million NIH grant to launch the iCure Consortium, developing individualized cure regimens for HIV through personalized medicine approaches.
Wistar Institute Scientists Develop Next-Generation DNA-LNP Vaccine Technology with Enhanced Immune Response
Scientists at The Wistar Institute, University of Pennsylvania, and INOVIO have successfully combined plasmid DNA with lipid nanoparticle delivery systems, overcoming previous stability and efficacy challenges.
INOVIO's DNA-Encoded Monoclonal Antibodies Show Durable 72-Week Expression Without Immune Rejection in COVID-19 Trial
INOVIO's Phase 1 trial demonstrates DNA-encoded monoclonal antibodies (DMAbs) maintained stable levels for 72 weeks in all participants, potentially overcoming the short half-life limitations of traditional antibody therapies.